A5014421573- Bone and Joint Diseases
- Hemoglobinopathies and Related Disorders
- Blood groups and transfusion
- Chronic Myeloid Leukemia Treatments
- Pharmacological Effects and Toxicity Studies
- Bone health and treatments
Zhuhai People's Hospital
2024
Jinan University
2024
Penn State Milton S. Hershey Medical Center
2010
Objective: We evaluated the long-term safety and efficacy of thalidomide in treatment transfusion-dependent β-thalassemia (TDT). Methods: Fifty patients with TDT were treated followed-up for 5 years. Thalidomide at a 50 mg dose was administered once day after dinner. The increased to 150 mg/d 3 d if well tolerated. After 1 year treatment, hemoglobin (Hb) level stabilized its maximum, gradually reduced maintained minimum dose. hematological response, transfusion dependence, haemolytic...